Curis Lifesciences IPO is a book-built issue worth ₹27.52 crore. The issue is entirely a fresh issue of 0.22 crore shares, raising the total issue size. The IPO will open for subscription on November 7, 2025, and close on November 11, 2025.
The basis of allotment is expected to be finalised on November 12, 2025, with tentative listing scheduled on NSE SME for November 14, 2025. The price band for the Curis Lifesciences IPO has been fixed between ₹120 to ₹128 per share.
Investors can bid for Curis Lifesciences IPO with a minimum of 2 lots of, each having 1,000 shares. For retail investors, the minimum investment required is ₹2,56,000. For small non-institutional investors (sNII), the lot size stands at 3 lots, equal to 3,000 shares, amounting to ₹3,84,000. For big non-institutional investors (bNII), the lot size is 8 lots, which translates to 8,000 shares, requiring an investment of ₹10,24,000.
Khambatta Securities Ltd is the book running lead manager (BRLM) and MUFG Intime India Pvt. Ltd. td is the registrar of the issue. Detailed information is available in the Curis Lifesciences IPO RHP.
Curis Lifesciences IPO Objectives
Curis Lifesciences will use the funds raised from the public issue for the following:
- Capital expenditure towards upgradation/improvement of the existing manufacturing facilities
- Capital expenditure towards construction of a storage facility
- Pre-payment/repayment of outstanding secured loans
- Product registrations in other countries
- Working capital requirements
- General corporate purposes
About Curis Lifesciences Limited
Incorporated in 2010, Curis Lifesciences is a pharmaceutical manufacturing company specialising in the production of a diverse range of pharmaceutical products, including tablets, capsules, external preparations, oral liquids, and sterile ophthalmic ointments. The company is engaged in both domestic and international markets, offering comprehensive manufacturing solutions through loan license manufacturing, contract manufacturing, and direct export/own brand marketing models.
Under loan license manufacturing, Curis Lifesciences undertakes production on behalf of client companies that supply all raw materials, excipients, and formulations. The manufacturing process is carried out under the supervision of the client’s appointed chemist, ensuring strict adherence to the provided specifications. In this arrangement, the company functions as a job-work manufacturer, delivering high-quality products as per client requirements.
In contract manufacturing, Curis Lifesciences assumes complete responsibility for procuring and managing raw materials, ingredients, and packaging materials. The company also handles all documentation and formulation processes necessary for production. While the client retains control over the brand name and product composition, all marketing and distribution activities remain with the client, allowing Curis Lifesciences to focus on quality-driven production.
Through its direct export and own brand manufacturing operations, the company manages the entire value chain—from sourcing raw materials and packaging to marketing and distribution—under its proprietary brands. The brand name and product composition are fully owned by Curis Lifesciences. The company currently exports its products under its own labels to international markets, including the Republic of Yemen and Kenya.
Curis Lifesciences operates a state-of-the-art manufacturing facility in Sanand, Gujarat, which adheres to stringent quality control standards to ensure the highest levels of product safety, consistency, and efficacy. This commitment to quality, combined with its flexible manufacturing models and growing global footprint, has positioned Curis Lifesciences as a reliable partner in the pharmaceutical manufacturing sector.
Industry Outlook
- The Indian pharmaceutical industry continues to demonstrate robust growth, with projections indicating an expansion of 9–11% in FY2024 as per ICRA. The industry’s market size is expected to reach US$65 billion by 2024, US$130 billion by 2030, and US$450 billion by 2047, reflecting its long-term potential.
- India holds a prominent position in the global pharmaceutical landscape, ranking third in the world by volume and 14th by value. It is a leading producer of generic drugs and low-cost vaccines, with a 57% contribution to the WHO’s prequalified API list and an 8% share in the global API market.
- The Indian pharmaceutical industry exports to over 200 countries, including regulated markets such as the USA, Europe, Japan, and Australia, making it one of the top ten most attractive sectors for foreign investment.
- Beyond pharmaceuticals, India’s medical devices sector is emerging as a key growth area, valued at US$11 billion in 2023 with a target of reaching US$50 billion by 2030.
How To Apply for the Curis Lifesciences IPO Online?
- Login to Your Angel One Account: Open the Angel One app or website and log in with your credentials.
- Locate the IPO Section: Navigate to the 'IPO' section on the platform.
- Select IPO: Find and select the Curis Lifesciences IPO from the list of open IPOs.
- Enter the Lot Size: Specify the number of lots you want to bid for.
- Submit Your UPI ID: Enter your UPI ID to link your payment method and submit your application.
- Approve Funds: Once you receive the bid request on your UPI app, approve it by entering your UPI PIN.
How To Check the Allotment Status of Curis Lifesciences IPO?
Steps to check IPO allotment status on Angel One’s app:
- Log in to the Angel One app.
- Go to the IPO Section and then to IPO Orders.
- Select the individual IPO that you had applied for and check the allotment status.
- Angel One will notify you of your IPO allotment status via push notification and email.
Contact Details of Curis Lifesciences IPO
PF-23, GIDC Sanand - II, Industrial Estate, Ahmedabad, Sanand, Gujarat-382110, India
Phone:+91 99045 22543
E-mail:cs@curisls.com
Curis Lifesciences IPO Reservation
| Investor Category | Shares Offered | % of Total Shares |
| Market Maker Shares Offered | 1,08,000 | 5.02% |
| QIB Shares Offered | 10,18,000 | 47.35% |
| NII (HNI) Shares Offered | 3,08,000 | 14.33% |
| Retail Shares Offered | 7,16,000 | 33.30% |
| Total Shares Offered | 21,50,000 | 100.00% |
Curis Lifesciences IPO Lot Size Details
| Application | Lots | Shares | Amount |
| Retail (Min) | 2 | 2,000 | ₹2,56,000 |
| Retail (Max) | 2 | 2,000 | ₹2,56,000 |
| S-HNI (Min) | 3 | 3,000 | ₹3,84,000 |
| S-HNI (Max) | 7 | 7,000 | ₹8,96,000 |
| B-HNI (Min) | 8 | 8,000 | ₹10,24,000 |
Curis Lifesciences IPO Promoter Holding
Mr. Dharmesh Dashrathbhai Patel, Mr. Siddhant Jayantibhai Pawasia, Mr. Piyush Gordhanbhai Antala and Mr. Jaimik Mansukhbhai Patel are the promoters of the company.
| Share Holding Pre-Issue | 92.68% |
| Share Holding Post Issue | 68.03% |
Note: Equity dilution will be determined by subtracting the Shareholding Post Issue from the Shareholding Pre Issue.
Key Performance Indicators for Curis Lifesciences IPO
| KPI | Value |
| ROE (%) | 55.25 |
| ROCE (%) | 27.83 |
| RoNW (%) | 37.62 |
| PAT Margin (%) | 12.43 |
| EBITDA Margin (%) | 19.41 |
Curis Lifesciences IPO Prospectus
Curis Lifesciences IPO Registrar and Lead Managers
Curis Lifesciences IPO Lead Managers
- Finaax Capital Advisors Private Limited
Registrar for Curis Lifesciences IPO
MUFG Intime India Pvt.Ltd
- Contact Number: +91 8108114949
- Email Address: curislifesciences.smeipo@in.mpms.mufg.com
Financial Performance of Curis Lifesciences Limited
| Particulars | Period Ended on July 31, 2025 | Year ending on March 31, 2025 | Year ending on March 31, 2024 | Year ending on March 31, 2023 |
| Revenue from Operations (in ₹ lakhs) | 1,950.39 | 4,913.24 | 3,555.57 | 3,544.88 |
| EBITDA (in ₹ lakhs) | 423.56 | 953.73 | 838.76 | 327.59 |
| EBITDA Margin (%) | 21.72 | 19.41 | 23.59 | 9.24 |
| Profit/loss After Tax (in ₹ lakhs) | 287.16 | 610.51 | 486.70 | 187.53 |
| PAT Margin (%) | 14.72 | 12.43 | 13.69 | 5.29 |
| Net Worth (in ₹ lakhs) | 1,909.90 | 1,622.75 | 587.28 | 100.58 |
| Debt Equity Ratio (x) | 0.80 | 0.96 | 2.91 | 16.10 |
Strengths and Opportunities of Curis Lifesciences Limited
- Promoters and management team with over 13–15 years of pharmaceutical industry experience, combining technical expertise with strategic business acumen.
- Broad range of formulations, including tablets, capsules, oral liquids, external preparations, and sterile ophthalmic ointments, catering to varied therapeutic needs.
- The ability to serve a wide range of industries and meet diverse customer needs reflects operational flexibility and customer satisfaction.
- Accredited by multiple global regulatory bodies, including WHO-GMP, Yemen’s Ministry of Health, Kenya PPB, Philippines FDA, and Nigeria NAFDAC.
- Increasing exports to markets across Asia, Africa, and Europe, with plans to further strengthen international presence.
- Focus on nurturing strong relationships with marketers and distributors to enhance market reach and brand credibility.
- Continuous addition of new, high-demand formulations to maintain competitiveness and capture emerging market segments.
- Commitment to superior service, consistent product quality, and proactive feedback mechanisms to ensure long-term customer satisfaction and loyalty.
Risks and Threats of Curis Lifesciences Limited
- Adverse changes in local, national, or global economic conditions may impact business performance and profitability.
- Rising competition from existing players and new entrants could pressure margins and affect market share.
- Delays or failures in securing necessary approvals, licenses, or permits can hinder operations and expansion plans.
- Political instability or changes in government policies may disrupt operations and overall business environment.
- Variations in market demand and supply dynamics could directly influence revenue generation.
- Alterations in pharmaceutical regulations or compliance requirements could affect production and distribution activities.
- Shifts in government priorities or trade policies could adversely affect business expansion and profitability.
- Any downgrade in India’s sovereign credit rating may negatively influence investor sentiment and financing costs.
